Hostname: page-component-55f67697df-zpzq9 Total loading time: 0 Render date: 2025-05-10T06:13:37.490Z Has data issue: false hasContentIssue false
  • English
  • Français

Cannabidiol improves non-motor symptoms, attenuates neuroinflammation, and favours hippocampal newborn neuronal maturation in a rat model of Parkinsonism

Published online by Cambridge University Press:  21 May 2024

Bianca Andretto de Mattos ,
Jéssica Mendes Bonato ,
Maria Clara Splendor ,
Elaine Del Bel ,
Humberto Milani  and
Rúbia Maria Weffort de Oliveira Open the ORCID record for Rúbia Maria Weffort de Oliveira [Opens in a new window]
Bianca Andretto de Mattos
Affiliation:
Department of Pharmacology and Therapeutics, State University of Maringá, Maringá, Paraná, Brazil
Jéssica Mendes Bonato
Affiliation:
Department of Pharmacology and Therapeutics, State University of Maringá, Maringá, Paraná, Brazil
Maria Clara Splendor
Affiliation:
Department of Pharmacology and Therapeutics, State University of Maringá, Maringá, Paraná, Brazil
Elaine Del Bel
Affiliation:
Department of Basic and Oral Biology, School of Medicine, USP, Ribeirão Preto, São Paulo, Brazil
Humberto Milani
Affiliation:
Department of Pharmacology and Therapeutics, State University of Maringá, Maringá, Paraná, Brazil
Rúbia Maria Weffort de Oliveira*
Affiliation:
Department of Pharmacology and Therapeutics, State University of Maringá, Maringá, Paraná, Brazil
*
Corresponding author: Rúbia Maria Weffort de Oliveira; Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To investigate the effects of cannabidiol (CBD) on emotional and cognitive symptoms in rats with intra-nigral 6-hydroxydopamine (6-OHDA) lesions.

Methods:

Adult male Wistar rats received bilateral intranigral 6-OHDA infusions and were tested in a battery of behavioural paradigms to evaluate non-motor symptoms. The brains were obtained to evaluate the effects of CBD on hippocampal neurogenesis.

Results:

6-OHDA-lesioned rats exhibited memory impairments and despair-like behaviour in the novelty-suppressed feeding test and forced swim test, respectively. The animals also exhibited dopaminergic neuronal loss in the substantia nigra pars compacta (SNpc), striatum, and ventral tegmental area and a reduction of hippocampal neurogenesis. CBD decreased dopaminergic neuronal loss in the SNpc, reduced the mortality rate and decreased neuroinflammation in 6-OHDA-lesioned rats. In parallel, CBD prevented memory impairments and attenuated despair-like behaviour that were induced by bilateral intranigral 6-OHDA lesions. Repeated treatment with CBD favoured the neuronal maturation of newborn neurons in the hippocampus in Parkinsonian rats.

Conclusion:

The present findings suggest a potential beneficial effect of CBD on non-motor symptoms induced by intra-nigral 6-OHDA infusion in rats.

Keywords

6-OHDA lesioncannabidiolmemoryhippocampalneurogenesisneuroinflammation
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 36 , Issue 5 , October 2024 , pp. 307 - 319
Check for updates
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Aarsland, D, Påhlhagen, S, Ballard, CG, Ehrt, U and Svenningsson, P (2011) Depression in Parkinson disease—epidemiology, mechanisms and management. Nature Reviews Neurology 8(1), 35–47. DOI: 10.1038/nrneurol.2011.189.CrossRefGoogle ScholarPubMed
Akkerman, S, Blokland, A, Reneerkens, O, van Goethem, NP, Bollen, E, Gijselaers, HJM, Lieben, CKJ, Steinbusch, HWM and Prickaerts, J (2012) Object recognition testing: methodological considerations on exploration and discrimination measures. Behavioural Brain Research 232(2), 335–347.CrossRefGoogle ScholarPubMed
Akkerman, S, Blokland, A, Reneerkens, O, van Goethem, NP, Bollen, E, Gijselaers, HJM, Lieben, CKJ, Steinbusch, HWM and Prickaerts, J (2012) Object recognition testing: methodological considerations on exploration and discrimination measures. Behavioural Brain Research 232(2), 335–347. DOI: 10.1016/j.bbr.2012.03.022.CrossRefGoogle ScholarPubMed
Alborghetti, M and Nicoletti, F (2019) Different generations of type-B monoamine oxidase inhibitors in Parkinson’s disease: from bench to bedside. Current Neuropharmacology 17(9), 861–873. DOI: 10.2174/1570159X16666180830100754.CrossRefGoogle ScholarPubMed
Blandini, F, Levandis, G, Bazzini, E, Nappi, G and Armentero, MT (2007) Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. European Journal of Neuroscience 25(2), 397–405. DOI: 10.1111/j.1460-9568.2006.05285.x.CrossRefGoogle ScholarPubMed
Blasco-Serra, A, González-Soler, EM, Cervera-Ferri, A, Teruel-Martí, V and Valverde-Navarro, AA (2017) A standardization of the novelty-suppressed feeding test protocol in rats. Neuroscience Letters 658, 73–78.CrossRefGoogle ScholarPubMed
Bonato, JM, Bassani, TB, Milani, H, Vital, MABF and de Oliveira, RMW (2018) Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson’s disease in rats. Experimental Neurology 300, 188–200.CrossRefGoogle ScholarPubMed
Bonito-Oliva, A, Masini, D and Fisone, G (2014) A mouse model of non-motor symptoms in Parkinson’s disease: focus on pharmacological interventions targeting affective dysfunctions. Frontiers in Behavioral Neuroscience 8, 290. DOI: 10.3389/fnbeh.2014.00290.CrossRefGoogle ScholarPubMed
Bové, J and Perier, C (2012) Neurotoxin-based models of Parkinson’s disease. Neuroscience 211, 51–76. DOI: 10.1016/j.neuroscience.2011.10.057.CrossRefGoogle ScholarPubMed
Brown, JP, Couillard-Després, S, Cooper-Kuhn, CM, Winkler, J, Aigner, L and Kuhn, HG (2003) Transient expression of doublecortin during adult neurogenesis. Journal of Comparative Neurology 467(1), 1–10.CrossRefGoogle ScholarPubMed
Camicioli, R, Moore, MM, Kinney, A, Corbridge, E, Glassberg, K and Kaye, JA (2003) Parkinson’s disease is associated with hippocampal atrophy. Movement Disorders 18(7), 784–790.CrossRefGoogle ScholarPubMed
Camicioli, R, Moore, MM, Kinney, A, Corbridge, E, Glassberg, K and Kaye, JA (2003) Parkinson’s disease is associated with hippocampal atrophy. Movement Disorders 18(7), 784–790. DOI: 10.1002/mds.10444.CrossRefGoogle ScholarPubMed
Campos, AC, Fogaça, MV, Sonego, AB and Guimarães, FS (2016) Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacological Research 112, 119–127. DOI: 10.1016/j.phrs.2016.01.033.CrossRefGoogle ScholarPubMed
Campos, AC, Ortega, Z, Palazuelos, J, Fogaça, MV, Aguiar, DC, Díaz-Alonso, J, Ortega-Gutiérrez, S, Vázquez-Villa, H, Moreira, FA, Guzmán, M, Galve-Roperh, I and Guimarães, FS (2013) The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. International Journal of Neuropsychopharmacology 16(6), 1407–1419. DOI: 10.1017/S1461145712001502.CrossRefGoogle ScholarPubMed
Celorrio, M, Rojo-Bustamante, E, Fernández-Suárez, D, Sáez, E, Estella-Hermoso de Mendoza, A, Müller, CE, Ramírez, MJ, Oyarzábal, J, Franco, R and Aymerich, MS (2017) GPR55: a therapeutic target for Parkinson’s disease? Neuropharmacology 125, 319–332. DOI: 10.1016/j.neuropharm.2017.08.017.CrossRefGoogle ScholarPubMed
Chagas, MHN, Zuardi, AW, Tumas, V, Pena-Pereira, MA, Sobreira, ET, Bergamaschi, MM, dos Santos, AC, Teixeira, AL, Hallak, JEC and Crippa, JAS (2014) Effects of cannabidiol in the treatment of patients with parkinson’s disease: an exploratory double-blind trial. Journal of Psychopharmacology 28(11), 1088–1098. DOI: 10.1177/0269881114550355.CrossRefGoogle ScholarPubMed
Chen, L, Liu, J, Zhang, QJ, Feng, JJ, Gui, ZH, Ali, U, Wang, Y, Fan, LL, Hou, C and Wang, T (2011) Alterations of emotion, cognition and firing activity of the basolateral nucleus of the amygdala after partial bilateral lesions of the nigrostriatal pathway in rats. Brain Research Bulletin 85(6), 329–338. DOI: 10.1016/j.brainresbull.2011.05.009.CrossRefGoogle ScholarPubMed
Chesworth, R, Cheng, D, Staub, C and Karl, T (2022) Effect of long-term cannabidiol on learning and anxiety in a female alzheimer’s disease mouse model. Frontiers in Pharmacology 13, 931384. DOI: 10.3389/fphar.2022.931384.CrossRefGoogle Scholar
Chia, SJ, Tan, EK and Chao, YX (2020) Historical perspective: models of Parkinson’s disease. International Journal of Molecular Sciences 21(7), 2464.CrossRefGoogle ScholarPubMed
Cilia, R, Cereda, E, Klersy, C, Canesi, M, Zecchinelli, AL, Mariani, CB, Tesei, S, Sacilotto, G, Meucci, N, Zini, M, Ruffmann, C, Isaias, IU, Goldwurm, S and Pezzoli, G (2015) Parkinson’s disease beyond 20 years. J Neurol Neurosurg Psychiatry 86(8), 849–855. DOI: 10.1136/jnnp-2014-308786.CrossRefGoogle ScholarPubMed
Coles, M, Watt, G, Kreilaus, F and Karl, T (2020) Medium-dose chronic cannabidiol treatment reverses object recognition memory deficits of APPSwe/PS1ΔE9 transgenic female mice. Frontiers in Pharmacology 11, 587604. DOI: 10.3389/fphar.2020.587604.CrossRefGoogle ScholarPubMed
Costa, C, Sgobio, C, Siliquini, S, Tozzi, A, Tantucci, M, Ghiglieri, V, Di Filippo, M, Pendolino, V, de Iure, A, Marti, M, Morari, M, Spillantini, MG, Latagliata, EC, Pascucci, T, Puglisi-Allegra, S, Gardoni, F, Di Luca, M, Picconi, B and Calabresi, P (2012) Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson’s disease. Brain 135(Pt 6), 1884–1899. DOI: 10.1093/brain/aws101.CrossRefGoogle ScholarPubMed
Crippa, JA, Guimarães, FS, Campos, AC and Zuardi, AW (2018) Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Frontiers in Immunology 9, 2009.CrossRefGoogle Scholar
Dalla, C, Pitychoutis, PM, Kokras, N and Papadopoulou-Daifoti, Z (2011) Sex differences in response to stress and expression of depressive-like behaviours in the rat. Current Topics in Behavioral Neurosciences 8, 97–118. DOI: 10.1007/7854_2010_94.CrossRefGoogle ScholarPubMed
Delaville, C, Chetrit, J, Abdallah, K, Morin, S, Cardoit, L, De Deurwaerdère, P and Benazzouz, A (2012) Emerging dysfunctions consequent to combined monoaminergic depletions in Parkinsonism. Neurobiology of Disease 45(2), 763–773. DOI: 10.1016/j.nbd.2011.10.023.CrossRefGoogle ScholarPubMed
Dos-Santos-Pereira, M, Guimarães, FS, Del-Bel, E, Raisman-Vozari, R and Michel, PP (2020) Cannabidiol prevents LPS-induced microglial inflammation by inhibiting ROS/NF-κB-dependent signaling and glucose consumption. Glia 68(3), 561–573. DOI: 10.1002/glia.23738.CrossRefGoogle ScholarPubMed
Esmaeili-Mahani, S, Haghparast, E, Nezhadi, A, Abbasnejad, M and Sheibani, V (2021) Apelin-13 prevents hippocampal synaptic plasticity impairment in Parkinsonism rats. Journal of Chemical Neuroanatomy 111, 101884. DOI: 10.1016/j.jchemneu.2020.101884.CrossRefGoogle ScholarPubMed
Hayakawa, K, Mishima, K, Irie, K, Hazekawa, M, Mishima, S, Fujioka, M, Orito, K, Egashira, N, Katsurabayashi, S, Takasaki, K, Iwasaki, K and Fujiwara, M (2008) Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 55(8), 1280–1286. DOI: 10.1016/j.neuropharm.2008.06.040.CrossRefGoogle Scholar
Hayes, MW, Fung, VS, Kimber, TE and O’Sullivan, JD (2019) Updates and advances in the treatment of Parkinson disease. The Medical Journal of Australia 211(6), 277–283. DOI: 10.5694/mja2.50224.CrossRefGoogle ScholarPubMed
Hooshangi Shayesteh, MR, Haghi-Aminjan, H, Baeeri, M, Rahimifard, M, Hassani, S, Gholami, M, Momtaz, S, Salami, SA, Armandeh, M, Bameri, B, Samadi, M, Mousavi, T, Ostad, SN and Abdollahi, M (2022) Modification of the hemodynamic and molecular features of phosphine, a potent mitochondrial toxicant in the heart, by cannabidiol. Toxicology Mechanisms and Methods 32(4), 288–301.CrossRefGoogle ScholarPubMed
Jones, NA, Hill, AJ, Smith, I, Bevan, SA, Williams, CM, Whalley, BJ and Stephens, GJ (2010) Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. Journal of Pharmacology and Experimental Therapeutics 332(2), 569–577. DOI: 10.1124/jpet.109.159145.CrossRefGoogle ScholarPubMed
Kalia, LV and Lang, AE (2016) Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. Nature Reviews Neurology 12(2), 65–66. DOI: 10.1038/nrneurol.2015.249.CrossRefGoogle ScholarPubMed
Khaksar, S, Bigdeli, M, Samiee, A and Shirazi-Zand, Z (2022) Antioxidant and anti-apoptotic effects of cannabidiol in model of ischemic stroke in rats. Brain Research Bulletin 180, 118–130. DOI: 10.1016/j.brainresbull.2022.01.00.CrossRefGoogle ScholarPubMed
Khaksar, S, Bigdeli, M, Samiee, A and Shirazi-Zand, Z (2022) Antioxidant and anti-apoptotic effects of cannabidiol in model of ischemic stroke in rats. Brain Research Bulletin 180, 118–130. DOI: 10.1016/j.brainresbull.2022.01.001.CrossRefGoogle ScholarPubMed
Kim, B, Weerasinghe-Mudiyanselage, PDE, Ang, MJ, Lee, J, Kang, S, Kim, J-C, Kim, S-H, Kim, J-S, Jung, C, Shin, T and Moon, C (2022) Changes in the neuronal architecture of the hippocampus in a 6-hydroxydopamine-lesioned rat model of parkinson disease. International Neurourology Journal 26(Suppl 2), S94–105. DOI: 10.5213/inj.2244252.126.CrossRefGoogle Scholar
Kreilaus, F, Przybyla, M, Ittner, L and Karl, T (2022) Cannabidiol (CBD) treatment improves spatial memory in 14-month-old female TAU58/2 transgenic mice. Behavioural Brain Research 425, 113812. DOI: 10.1016/j.bbr.2022.113812.CrossRefGoogle ScholarPubMed
Kundrick, ER, Marrero-Rosado, BM, de Araujo Furtado, M, Stone, M, Schultz, CR and Lumley, LA (2021) Cannabidiol reduces soman-induced lethality and seizure severity in female plasma carboxylesterase knockout mice treated with midazolam. Neurotoxicology 82, 130–136. DOI: 10.1016/j.neuro.2020.12.002.CrossRefGoogle ScholarPubMed
Lastres-Becker, I, Molina-Holgado, F, Ramos, JA, Mechoulam, R and Fernández-Ruiz, J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiology of Disease 19(1-2), 96–107. DOI: 10.1016/j.nbd.2004.11.009.CrossRefGoogle ScholarPubMed
Lastres-Becker, I, Molina-Holgado, F, Ramos, JA, Mechoulam, R and Fernández-Ruiz, J (2005 Jun-Jul) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to parkinson’s disease. Neurobiology of Disease 19(1-2), 96–107. DOI: 10.1016/j.nbd.2004.11.009.CrossRefGoogle ScholarPubMed
Lau, C, Hebert, M, Vani, MA, Walling, S, Hayley, S, Lagace, DC and Blundell, J (2016) Absence of neurogenic response following robust predator-induced stress response. Neuroscience 339, 276–286. Dec https://doi.org/10.1016/j.neuroscience.2016.10.001.CrossRefGoogle ScholarPubMed
Lee, A and Gilbert, RM (2016) Epidemiology of Parkinson disease. Neurologic Clinics 34(4), 955–965. DOI: 10.1016/j.ncl.2016.06.012.CrossRefGoogle ScholarPubMed
Lee, Y, Lee, S, Chang, S-C and Lee, J (2019) Significant roles of neuroinflammation in Parkinson’s disease: therapeutic targets for PD prevention. Archives of Pharmacal Research 42(5), 416–425. DOI: 10.1007/s12272-019-01133-0.CrossRefGoogle ScholarPubMed
Lim, J, Bang, Y and Choi, HJ (2018) Abnormal hippocampal neurogenesis in Parkinson’s disease: relevance to a new therapeutic target for depression with Parkinson’s disease. Archives of Pharmacal Research 41(10), 943–954.CrossRefGoogle ScholarPubMed
Lindner, MD, Cain, CK, Plone, MA, Frydel, BR, Blaney, TJ, Emerich, DF and Hoane, MR (1999) Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behavioural Brain Research 102(1-2), 1–16. DOI: 10.1016/s0166-4328(98)00160-0.CrossRefGoogle ScholarPubMed
Martínez-Martín, P and Damián, J (2010) Parkinson disease: depression and anxiety in Parkinson disease. Nature Reviews Neurology 6(5), 243–245. DOI: 10.1038/nrneurol.2010.49.CrossRefGoogle ScholarPubMed
Marxreiter, F, Regensburger, M and Winkler, J (2013) Adult neurogenesis in Parkinson’s disease. Cellular and Molecular Life Sciences 70(3), 459–473.CrossRefGoogle ScholarPubMed
Meyer, E, Bonato, JM, Mori, MA, Mattos, BA, Guimarães, FS, Milani, H, de Campos, AC and de Oliveira, RMW (2021) Cannabidiol confers neuroprotection in rats in a model of transient global cerebral ischemia: impact of hippocampal synaptic neuroplasticity. Molecular Neurobiology 58(10), 5338–5355.CrossRefGoogle Scholar
Mishima, K, Hayakawa, K, Abe, K, Ikeda, T, Egashira, N, Iwasaki, K and Fujiwara, M (2005) Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 36(5), 1077–1082. DOI: 10.1161/01.STR.0000163083.59201.34.CrossRefGoogle Scholar
Mori, MA, Meyer, E, da Silva, FF, Milani, H, Guimarães, FS and Oliveira, RMW (2021) Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments. European Journal of Neuroscience 53(6), 1738–1751.CrossRefGoogle ScholarPubMed
Mori, MA, Meyer, E, Soares, LM, Milani, H, Guimarães, FS and de Oliveira, RMW (2017) Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 75, 94–105.CrossRefGoogle ScholarPubMed
Muhammad, F, Liu, Y, Wang, N, Zhao, L, Zhou, Y, Yang, H and Li, H (2022) Neuroprotective effects of cannabidiol on dopaminergic neurodegeneration and α-synuclein accumulation in C. elegans models of Parkinson’s disease. Neurotoxicology 93, 128–139. DOI: 10.1016/j.neuro.2022.09.001.CrossRefGoogle Scholar
Pabon, MM, Bachstetter, AD, Hudson, CE, Gemma, C and Bickford, PC (2011) CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson’s disease. Journal of Neuroinflammation 8(1), 9. DOI: 10.1186/1742-2094-8-9.CrossRefGoogle Scholar
Padovan-Neto, FE, Echeverry, MB, Tumas, V and Del-Bel, EA (2009) Nitric oxide synthase inhibition attenuates l-DOPA-induced dyskinesias in a rodent model of Parkinson’s disease. Neuroscience 159(3), 927–935. DOI: 10.1016/j.neuroscience.2009.01.034.CrossRefGoogle Scholar
Patra, PH, Serafeimidou-Pouliou, E, Bazelot, M, Whalley, BJ, Williams, CM and McNeish, AJ (2020) Cannabidiol improves survival and behavioural co-morbidities of dravet syndrome in mice. British Journal of Pharmacology 177(12), 2779–2792. DOI: 10.1111/bph.15003.CrossRefGoogle ScholarPubMed
Patricio, F, Morales Dávila, E, Patricio-Martínez, A, Arana Del Carmen, N, Martínez, I, Aguilera, J, Perez-Aguilar, JM and Limón, ID (2022) Intrapallidal injection of cannabidiol or a selective GPR55 antagonist decreases motor asymmetry and improves fine motor skills in hemiparkinsonian rats. Frontiers in Pharmacology 13, 945836. DOI: 10.3389/fphar.2022.945836.CrossRefGoogle ScholarPubMed
Patricio, F, Morales-Andrade, AA, Patricio-Martínez, A and Limón, ID (2020) Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in parkinson’s disease. Frontiers in Pharmacology 11, 595635. DOI: 10.3389/fphar.2020.595635.CrossRefGoogle ScholarPubMed
Paxinos, G and Watson, C (2007) The rat brain in stereotaxic coordinates, 7 edn. Elsevier Science.Google Scholar
Perez, M, Cartarozzi, LP, Chiarotto, GB, Guimarães, FS and Oliveira, ALR (2021) Short and long-term neuroprotective effects of cannabidiol after neonatal peripheral nerve axotomy. Neuropharmacology 197, 108726. DOI: 10.1016/j.neuropharm.2021.108726.CrossRefGoogle Scholar
Plümpe, T, Ehninger, D, Steiner, B, Klempin, F, Jessberger, S, Brandt, M, Römer, B, Rodriguez, GR, Kronenberg, G and Kempermann, G (2006) Variability of doublecortin-associated dendrite maturation in adult hippocampal neurogenesis is independent of the regulation of precursor cell proliferation. BMC Neuroscience 7(1), 77.CrossRefGoogle ScholarPubMed
Poewe, W, Seppi, K, Tanner, CM, Halliday, GM, Brundin, P, Volkmann, J, Schrag, A-E and Lang, AE (2017) Parkinson disease. Nature Reviews Disease Primers 3(1), 17013.CrossRefGoogle ScholarPubMed
Sales, AJ, Crestani, CC, Guimarães, FS and Joca, SRL (2018) Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels. Progress in Neuro-Psychopharmacology and Biological Psychiatry 86, 255–261. DOI: 10.1016/j.pnpbp.2018.06.002.CrossRefGoogle ScholarPubMed
Santiago, RM, Barbieiro, J, Lima, MMS, Dombrowski, PA, Andreatini, R and Vital, MAF (2010) Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of parkinson’s disease are predominantly associated with serotonin and dopamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 34(6), 1104–1114. DOI: 10.1016/j.pnpbp.2010.06.004.CrossRefGoogle ScholarPubMed
Santiago, RM, Tonin, FS, Barbiero, J, Zaminelli, T, Boschen, SL, Andreatini, R, Da Cunha, C, Lima, MMS and Vital, MABF (2015) The nonsteroidal anti-inflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model os Parkinson’s disease. Neuroscience 300, 246–253.CrossRefGoogle Scholar
Santos García, D, Jesús, S, Aguilar, M, Planellas, LL, García Caldentey, J, Caballol, N, Legarda, I, Hernández Vara, J, Cabo, I, López Manzanares, L, González Aramburu, I, Ávila Rivera, MA, Catalán, MJ, López Díaz, L, Puente, V, García Moreno, JM, Borrué, C, Solano Vila, B, Álvarez Sauco, M, Vela, L, Escalante, S, Cubo, E, Carrillo Padilla, F, Martínez Castrillo, JC, Sánchez Alonso, P, Alonso Losada, MG, López Ariztegui, N, Gastón, I, Kulisevsky, J, Menéndez González, M, Seijo, M, Rúiz Martínez, J, Valero, C, Kurtis, M, de Fábregues-Boixar, O, González Ardura, J, Prieto Jurczynska, C, Martinez-Martin, P, Mir, P and on behalf of the COPPAIDS Study Group (2019) COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015): an ongoing global Parkinson’s disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation. European Journal of Neurology 26(11), 1399–1407. DOI: 10.1111/ene.14008.CrossRefGoogle ScholarPubMed
Schapira, AHV, Chaudhuri, KR and Jenner, P (2017) Non-motor features of Parkinson disease. Nature Reviews Neuroscience 18(7), 435–450.CrossRefGoogle ScholarPubMed
Schiavon, AP, Bonato, JM, Milani, H, Guimarães, FS and Weffort de Oliveira, RM (2016) Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry 64, 27–34. DOI: 10.1016/j.pnpbp.2015.06.017.CrossRefGoogle ScholarPubMed
Simola, N, Morelli, M and Carta, AR (2007) The 6-hydroxydopamine model of Parkinson’s disease. Neurotoxicity Research 11(3-4), 151–167.CrossRefGoogle ScholarPubMed
Singh, J and Neary, JP (2020) Neuroprotection following concussion: the potential role for cannabidiol. Canadian Journal of Neurological Sciences 47(3), 289–300. DOI: 10.1017/cjn.2020.23.CrossRefGoogle ScholarPubMed
Soares, LM, De Vry, J, Steinbusch, HWM, Milani, H, Prickaerts, J and Weffort de Oliveira, RM (2016) Rolipram improves cognition, reduces anxiety- and despair-like behaviors and impacts hippocampal neuroplasticity after transient global cerebral ischemia. Neuroscience 326, 69–83. DOI: 10.1016/j.neuroscience.2016.03.062.CrossRefGoogle ScholarPubMed
Tieu, K (2011) A guide to neurotoxic animal models of parkinson’s disease, vol. 1. Cold Spring Harb Perspect Med, a009316. DOI:10.1101/cshperspect.a009316.Google ScholarPubMed
Vieira, JCF, Bassani, TB, Santiago, RM, de O. Guaita, G, Zanoveli, Jína M, da Cunha, C and Vital, MABF (2019) Anxiety-like behavior induced by 6-OHDA animal model of Parkinson’s disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety. Behavioural Brain Research 371, 111981.CrossRefGoogle ScholarPubMed
Vilela, LR, Gomides, LF, David, BA, Antunes, MM, Diniz, AB, Moreira Fício de, A and Menezes, GB (2015) Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. Mediators of Inflammation 2015, 523418. DOI: 10.1155/2015/523418.CrossRefGoogle ScholarPubMed
Vivanco-Estela, AN, Dos-Santos-Pereira, M, Guimaraes, FS, Del-Bel, E and Nascimento, GCD (2021) Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats. Neuropharmacology 196, 108700. DOI: 10.1016/j.neuropharm.2021.108700.CrossRefGoogle ScholarPubMed
Watt, G and Karl, T (2017) In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer’s disease. Frontiers in Pharmacology 8, 20. DOI: 10.3389/fphar.2017.00020.CrossRefGoogle ScholarPubMed
WHO (2022) Launch of WHO’s Parkinson disease technical brief. Available at “https://www.who.int/news/item/14-06-2022-launch-of-who-s-parkinson-disease-technical-brief” (accessed 24 July 2023).Google Scholar
Wolf, SA, Bick-Sander, A, Fabel, K, Leal-Galicia, P, Tauber, S, Ramirez-Rodriguez, G, Müller, A, Melnik, A, Waltinger, TP, Ullrich, O and Kempermann, G (2010) Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Communication and Signaling 8, 12. DOI: 10.1186/1478-811X-8-12.CrossRefGoogle ScholarPubMed
Yousaf, M, Chang, D, Liu, Y, Liu, T and Zhou, X (2022) Neuroprotection of cannabidiol, Its synthetic derivatives and combination preparations against microglia-mediated neuroinflammation in neurological disorders. Molecules 27(15), 4961. DOI: 10.3390/molecules27154961.CrossRefGoogle ScholarPubMed
Zanelati, TV, Biojone, C, Moreira, FA, Guimarães, FS and Joca, SRL (2010) Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. British Journal of Pharmacology 159(1), 122–128.CrossRefGoogle ScholarPubMed